EPYGON is the first native-like transcatheter mitral valve replacement technology aiming at achieving better clinical outcomes The Austrian Competent Authority has granted authorization to start patient enrollment at Vienna General Hospital (AKH) The EPYGON valve has the potential to become a new paradigm in the treatment of functional mitral regurgitation […]
Coronary/Structural Heart
Windtree Announces Initial European Trial Sites Activated in AEROSURF® Bridging Study and a Collaboration for a Concomitant Independent Cerebral Physiology Study
WARRINGTON, Pa., June 24, 2020 /PRNewswire/ — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, today announced that all initial European trial sites are active and enrolling or able to enroll patients into […]
preCARDIA, Inc. Receives FDA Breakthrough Device Designation for Novel, Catheter Based Heart Failure Treatment
Pioneering technology is designed to address Acute Decompensated Heart Failure ST. PAUL, Minn., June 23, 2020/PRNewswire/ — preCARDIA, Inc., has announced that the company’s catheter based system for treating volume overload in patients with acutely decompensated heart failure (ADHF) has been designated for the Breakthrough Devices Program by the U.S. […]
Miracor Medical’s PiCSO® System Receives CE Mark
AWANS, Belgium–(BUSINESS WIRE)–Miracor Medical SA (Miracor Medical) has announced the award of the CE Mark for its latest generation of PiCSO Impulse Catheter and PiCSO Impulse Console, which is indicated for the treatment of anterior STEMI patients. The new system features improvements in ease of use. PiCSO therapy is delivered […]
TARA Biosystems Announces $10 Million Series A2 Financing to Expand its Cardiac Disease Drug Discovery and Development Capabilities
NEW YORK–(BUSINESS WIRE)–TARA Biosystems, Inc., a company generating in vitro human biology to increase the success of cardiac disease drug discovery and development, today announced a $10 million Series A2 financing. This financing will be used to scale TARA’s cardiac tissue engineering platform technology and advance its drug discovery programs. New investors […]
Medtronic Evolut TAVI System Receives Expanded Indication in Europe to Treat Severe Aortic Stenosis Patients at Low Risk for Surgical Mortality
he Evolut TAVI Platform Receives New Indication for Patients with Bicuspid Aortic Valves at Extreme, High or Intermediate Risk of Surgical Mortality DUBLIN, June 22, 2020 (GLOBE NEWSWIRE) — Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced CE (Conformité Européenne) mark and European launch of the Evolut™ Transcatheter […]
MyoKardia Announces Positive Data from Phase 2a Clinical Trial of Danicamtiv Presented at ESC’s HFA Discoveries with Simultaneous Publication in European Journal of Heart Failure
Danicamtiv was Well Tolerated; Demonstrated Improvements in Cardiac Contractility and Preserved Diastolic Function in Patients with Stable Heart Failure with Reduced Ejection Fraction New Observations Show Improvements in Left Atrial Volume and Function, Key Prognostic Indicators of Atrial Fibrillation Additional Nonclinical Studies Also Presented Demonstrating Danicamtiv’s Differentiated Mechanistic Profile Including Direct […]
Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study
CALGARY, Alberta, June 22, 2020 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix”) (TSX:RVX) is pleased to announce that the U.S. Food & Drug Administration (FDA) has accepted its BETonMACE2 clinical plan as a registration enabling study with positive implications for Resverlogix and its ongoing partnership discussions. Key written development points from […]
MedAlliance Gains CE Mark Approval for Coronary SELUTION SLR™ Sirolimus Drug Eluting Balloon
MUMBAI, India, June 16, 2020 /PRNewswire/ — MedAlliance has announced the award of its second CE Mark: SELUTION SLR™ 014 PTCA, a novel Sirolimus Drug Eluting Balloon (DEB), for the treatment of coronary arterial disease. This includes indications for both de-novo lesions as well as in-stent restenosis. The approval applies to a broad […]
Abiomed Launches Virtual Physician Education Program, CAMP PCI, to Improve High-Risk PCI Patient Outcomes
DANVERS, Mass.–(BUSINESS WIRE)–Today, Abiomed (NASDAQ: ABMD) launches a cutting-edge digital education platform called CAMP PCI, which stands for Coronary Artery & Myocardial Protected Percutaneous Coronary Intervention, to improve patient outcomes and quality of life with supported high-risk PCI by utilizing best practices, techniques and technologies to enable safer, more effective and complete revascularization. […]



